Form 4: Vaxart Director Elaine Heron Acquires 40,000 Shares
Insider Transaction Report
Vaxart Director Elaine Heron reported the acquisition of 40,000 shares of common stock on November 17, 2025, through a pre-arranged Rule 10b5-1 trading plan.
Summary
- Director Elaine J. Heron acquired a total of 40,000 shares of Vaxart, Inc. common stock.
- These transactions occurred on November 17, 2025, and were made pursuant to a Rule 10b5-1 trading plan.
- The first acquisition involved 23,217 shares at a price of $0.393 per share.
- The second acquisition involved 16,783 shares at a price of $0.405 per share.
- Following these reported transactions, Elaine J. Heron directly beneficially owns 96,566 shares of Vaxart, Inc. common stock.
- The Form 4 filing was signed by Edward Berg, acting as Attorney-in-Fact for Elaine Heron, on November 19, 2025.
Sentiment
Score: 7
Explanation: The acquisition of 40,000 shares by a director, even under a pre-arranged 10b5-1 plan, signals a positive long-term outlook and commitment to the company's value, which is generally viewed favorably by the market.
Positives
- A director's acquisition of shares, even under a pre-arranged 10b5-1 plan, demonstrates a planned commitment and long-term confidence in the company's future prospects.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Elaine J. Heron granted power of attorney to Steven Lo, Phillip Lee, Edward B. Berg, and Faith L. Charles to execute and file Forms 3, 4, and 5 on her behalf. | 03/05/2025 | This streamlines compliance with Section 16(a) of the Securities Exchange Act of 1934 for the director, ensuring timely and accurate filings. |
Stakeholder Impact
- Shareholders may interpret this insider buying as a positive signal, potentially increasing confidence in the company's stock and future performance.
Key Dates
| Date | Description |
|---|---|
| 03/05/2025 | Elaine J. Heron executed a Power of Attorney, authorizing individuals to file SEC Forms on her behalf. |
| 11/17/2025 | Date of the reported stock acquisition transactions by Elaine J. Heron. |
| 11/19/2025 | Date the Form 4 was signed by the Attorney-in-Fact. |
Recommendation
buyThe director's decision to acquire a substantial number of shares, even through a pre-arranged 10b5-1 plan, suggests strong internal confidence in Vaxart's long-term prospects. This insider commitment, particularly at these price levels, could be seen as an attractive indicator for investors considering an entry or increasing their position.
Keywords
Vaxart, VXRT, Elaine Heron, insider buying, director, stock acquisition, SEC Form 4, beneficial ownership, 10b5-1 plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.